Low‐dose colchicine vs NSAIDs: Number of participants reporting an adverse event
Low‐dose colchicine showed no clear difference in total number of participants reporting adverse events compared with NSAIDs (low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Low‐dose colchicine vs NSAIDs Total number of participants reporting adverse events · people with acute gout Low‐dose colchicine showed no clear difference in total number of participants reporting adverse events compared with NSAIDs (low certainty). Colchicine for acute gout (2021) · Cochrane Headline outcomes only | RR 1.07 [0.88, 1.29] | 1 study · 399 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Colchicine for acute gout 2021 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.